Over the past 10 years, the survival and quality of life of patients receiving treatment for MM have greatly improved due to the development of new MM therapies using various targeted inhibitors for BRAFV600E and MEK kinases as well as immune-based strategies [4,5,6,7]. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.